BMC Infectious Diseases

Table 2 Donor screening tests for HIV, HCV, and HBV from 2000 to 2010

From: Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010
HIV
anti-HIV (EIA)	DA^*	DA	DA	GC^†	GC	LG/GC^‡	LG/GC	LG/BioRad	LG/BioRad	LG	LG
HIV-NAT						Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron
HCV
anti-HCV (EIA)	LG/SI^§	LG/SI	LG/SI	LG	LG/DA	SI/LG	LG	LG	LG	LG	LG
HCV-NAT						Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron	Roche/Chiron
HBV
HBsAg (EIA/CLIA)	DA/GC	DA/GC	DA/GC	GC/DA	GC	GC/LG	BioRad/SI	Abbott	Abbott	Abbott	Abbott

^*DA, Dong-A Pharm.
^†GC, Green Cross co.
^‡LG, LG Corp.
^§SI, Samil co. LTD.

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com